The challenge of assuring continued post-trial access to beneficial treatment

Yale J Health Policy Law Ethics. Winter 2005;5(1):425-35.
No abstract available

MeSH terms

  • Anti-HIV Agents / supply & distribution
  • Clinical Trials as Topic / ethics*
  • Continuity of Patient Care / ethics*
  • Drugs, Investigational / administration & dosage
  • Drugs, Investigational / supply & distribution*
  • Ethics, Research*
  • Global Health
  • Guidelines as Topic
  • Health Services Accessibility / ethics*
  • Humans
  • International Agencies
  • International Cooperation*
  • Moral Obligations*
  • Quality Assurance, Health Care / ethics
  • Therapeutic Human Experimentation / ethics*
  • United States

Substances

  • Anti-HIV Agents
  • Drugs, Investigational